About
Bispecific Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyChina
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
443
By Phase
PHASE1/PHASE2: 1PHASE3: 1
By Status
UNKNOWN: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT04799847Lead Sponsor
Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine
PHASE1/PHASE2Unknown
161 participants
Started: Nov 23, 2021 · Completed: Nov 30, 2024
NCT04222114Lead Sponsor
Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis
PHASE3Unknown
282 participants
Started: Oct 6, 2020 · Completed: Aug 31, 2023
Locations (1)
Headquarters
Guangzhou, China
Map
Loading map...